2747918-37-0
Chemical Structure
Bilastine-d4
- CAS No.: 2747918-37-0
- Formula:C28H33D4N3O3
- Molecular Weight:467.64
IUPAC Name: 2-(4-(2-(4-(1-(2-ethoxyethyl-1,1,2,2-d4)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-methylpropanoic acid
InChIKey: ACCMWZWAEFYUGZ-SKIVKWGGSA-N
SMILES: CC(C)(C1=CC=C(CCN2CCC(C3=NC4=CC=CC=C4N3C([2H])([2H])C([2H])([2H])OCC)CC2)C=C1)C(O)=O
Biological Activity: Bilastine-d4 is deuterium labeled Bilastine. Bilastine is an oral histamine H1-receptor antagonist. Bilastine can be used for allergic rhinitis and urticaria studies, and it also improves diabetic nephropathy in mice, showing safety for the central nervous system[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bilastine-d4 | Bilastine-d4 is deuterium labeled Bilastine. Bilastine is an oral histamine H1-receptor antagonist. Bilastine can be used for allergic rhinitis and urticaria studies, and it also improves diabetic nephropathy in mice, showing safety for the central nervous system. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bilastine (Standard) | ≥98% | Bilastine (Standard) is the analytical standard of Bilastine. This product is intended for research and analytical applications. Bilastine is a histamine H1 receptor antagonist that can be used to treat allergic rhinoconjunctivitis and urticaria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bilastine-d6 | 97.12% | Bilastine-d6 is the deuterium labeled Bilastine. Bilastine is a selective histamine H1 receptor antagonist used for treatment of allergic rhinoconjunctivitis and urticaria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bilastine | 99.83% | Bilastine is an oral histamine H1-receptor antagonist. Bilastine can be used for allergic rhinitis and urticaria studies, and it also improves diabetic nephropathy in mice, showing safety for the central nervous system. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. C. Bachert, et al. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy.19 May 2010
- [3]. María Luisa Lucero, et al. Preclinical toxicity profile of oral bilastine. Drug Chem Toxicol. 2012 Jun:35 Suppl 1:25-33. [Content Brief]
- [4]. Roberta Verta, et al. Effect of Bilastine on Diabetic Nephropathy in DBA2/J Mice. Int J Mol Sci. 2019 May 24;20(10):2554. [Content Brief]
- [5]. J Montoro, et al. Bilastine and the central nervous system. J Investig Allergol Clin Immunol. J Investig Allergol Clin Immuno [Content Brief]
